Premium
CSF Aβ 42 and tau in Parkinson's disease with cognitive impairment
Author(s) -
Montine Thomas J.,
Shi Min,
Quinn Joseph F.,
Peskind Elaine R.,
Craft Suzanne,
Ginghina Carmen,
Chung Kathryn A.,
Kim Hojoong,
Galasko Douglas R.,
Jankovic Joseph,
Zabetian Cyrus P.,
Leverenz James B.,
Zhang Jing
Publication year - 2010
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.23287
Subject(s) - parkinson's disease , dementia , cognitive impairment , medicine , biomarker , psychology , alzheimer's disease , oncology , gastroenterology , disease , biology , biochemistry
We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD‐D) or with PD and Cognitive Impairment, Not Dementia (PD‐CIND). We quantified CSF Aβ 42 , total tau (T‐tau), and phospho‐tau (P181‐tau) using commercially available kits. Samples were from 345 individuals in seven groups ( n ): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD‐CIND (62), and PD‐D (11). We observed expected changes in AD or aMCI compared with age‐matched or younger controls. CSF Aβ 42 was reduced in PD‐CIND ( P < 0.05) and PD‐D ( P < 0.01), whereas average CSF T‐tau and P181‐tau were unchanged or decreased. One‐third of PD‐CIND and one‐half of PD‐D patients had the biomarker signature of AD. Abnormal metabolism of Aβ 42 may be a common feature of PD‐CIND and PD‐D. © 2010 Movement Disorder Society